---
title: "Key facts: Esperion Expands 2024–25 Programs; Estimates Fall 781.6%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285820903.md"
description: "Esperion (ESPR) advanced clinical programs in 2024–2025, including a pediatric trial, and secured expanded indications and international approvals to support broader market access for its products.1Esperion (ESPR) saw mean earnings estimates plunge about 781.6% over three months; one analyst cut their estimate in the past 30 days.2"
datetime: "2026-05-09T20:03:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285820903.md)
  - [en](https://longbridge.com/en/news/285820903.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285820903.md)
generator: "portal-rs"
---

# Key facts: Esperion Expands 2024–25 Programs; Estimates Fall 781.6%

-   Esperion (ESPR) advanced clinical programs in 2024–2025, including a pediatric trial, and secured expanded indications and international approvals to support broader market access for its products.1
-   Esperion (ESPR) saw mean earnings estimates plunge about 781.6% over three months; one analyst cut their estimate in the past 30 days.2

### Related Stocks

- [ESPR.US](https://longbridge.com/en/quote/ESPR.US.md)

## Related News & Research

- [Esperion acquired in cash-and-CVR merger transaction](https://longbridge.com/en/news/292521304.md)
- [Archimed completes take-private of Esperion in deal valued up to $1.1 billion](https://longbridge.com/en/news/292496629.md)
- [14:06 ETStarlight Children's Foundation Announces 2026 Starlight Awards Honorees](https://longbridge.com/en/news/296524956.md)
- [The ripple effects of the Iran war could threaten education for millions of kids around the world](https://longbridge.com/en/news/296112167.md)
- [FDA accepts Teva ecopipam NDA for pediatric Tourette syndrome, grants priority review](https://longbridge.com/en/news/296355997.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**